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Background: Epithelioid sarcoma (EpS) is a high-grade malignant soft-tissue sarcoma characterized by local
recurrences and distant metastases. Effective treatments for EpS have not been established and thus novel therapeutic
approaches against EpS are urgently required. mTOR inhibitors exert antitumor effects on several malignancies but
AKT reactivation by mTOR inhibition attenuates the antitumor effects of mTOR inhibitors. This reactivation is receptor
tyrosine kinase (RTK)-dependent due to a release of negative feedback inhibition. We found that c-MET was the most
highly activated RTK in two human EpS cell lines, Asra-EPS and VAESBJ. Here we investigated the functional and
therapeutic relevance of mTOR and/or c-MET signaling pathways in EpS both in vitro and in vivo.
Methods: We first examined the effects of an mTOR inhibitor, RAD001 (everolimus), on cell proliferation, cell cycle,
AKT/mTOR signaling, and xenograft tumor growth in EpS cell lines. Next, we determined whether RAD001-induced
AKT reactivation was blocked by silencing of c-MET or treatment with a selective c-MET inhibitor, INC280. Finally, we
evaluated the antitumor effects of RAD001 combined with INC280 on EpS cell lines compared with either single agent
or control in vitro and in vivo.
Results: Constitutive AKT phosphorylation was observed in Asra-EPS and VAESBJ cells. RAD001 suppressed EpS cell
growth by inducing cell cycle arrest but enhanced AKT phosphorylation, which resulted in intrinsic resistance to mTOR
inhibitors. In both EpS cell lines, RAD001-induced AKT phosphorylation was dependent on c-MET signaling. INC280
inhibited phosphorylation of c-MET and its downstream molecules, and decreased RAD001-induced phosphorylation
of both AKT and ERK in EpS. Compared with a single agent or control, the combination of RAD001 and INC280 exerted
superior antitumor effects on the growth of EpS cell lines in vitro and in vivo.
Conclusions: Targeting of mTOR and c-MET signaling pathways significantly abrogates the growth of EpS in preclinical
models and may be a promising therapeutic approach for patients with EpS.
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Epithelioid sarcoma (EpS) was first described in 1970 by
Enzinger as a distinct soft-tissue tumor with mixed
epithelial and mesenchymal phenotype [1], but the
origin and true nature of EpS remain controversial. In
general, EpS is relatively rare and accounts for less
than 1% of all soft-tissue sarcomas [2]. The overall 5-year
survival rates are 32%–78% [2-5]. The clinical course of
EpS is usually characterized by local recurrences and
distant metastases to lymph nodes and lungs, but an
effective chemotherapy has not yet been established
[2-5]. Therefore, novel therapeutic approaches against
EpS are critically needed.
The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR
signaling pathway, which drives cell proliferation, motility,
and survival, is frequently hyperactivated in a variety of
malignancies [6,7], and inhibition of this pathway has been
considered an appropriate approach for cancer therapy.
Integrase interactor 1 (INI-1) is the protein product of the
tumor suppressor gene hSNF5/INI1/SMARCB1/BAF47
located on 22q11.2. Loss of INI-1 serves as a diagnostic
feature in malignant rhabdoid tumors (MRTs) and atypical
teratoid/rhabdoid tumors (AT/RTs) [8,9]. Darr and
colleagues reported that INI-1-deficient tumor cells
exhibited persistent activation of AKT signaling [10].
INI-1 expression is also lost in most EpS clinical samples
[11,12], suggesting that AKT signaling may also be
activated in EpS cells. In the present study, we detected
loss of INI-1 expression and constitutive AKT activation in
two human EpS cell lines, Asra-EPS [13] and VAESBJ [14].
AKT activation has been proposed as a predictor of
response to rapamycin, which is an allosteric mTOR
inhibitor [15]; this concept raises the possibility that
mTOR inhibitors may be effective on EpS. Administration
of these drugs results in reduction of regulatory proteins
involved in progression of cells from the G1 to S-phase of
their growth cycle [16]. The U.S. Food and Drug
Administration has approved mTOR inhibitors for
treatment of neuroendocrine tumors, renal cell carcinoma,
and subependymal giant cell astrocytoma associated with
tuberous sclerosis. However, the antitumor effects of
mTOR inhibitors on patients with bone or soft-tissue
sarcomas are limited, and responses are frequently
short lived [17,18]. In addition, blocking mTOR activity
inadvertently reactivates AKT signaling, which mitigates
the antitumor effects of mTOR inhibitors, and this
reactivation has been posited as a mechanism of intrinsic
resistance to mTOR inhibitors [19-22].
The AKT/mTOR signaling pathway is normally regulated
by upstream receptor tyrosine kinases (RTKs) [23-25].
The resistance to mTOR inhibitors has been reported
to be caused by RTK-dependent AKT reactivation due
to a release of negative feedback inhibition [19-22].
Overexpression of hepatocyte growth factor (HGF)and its receptor, known as c-MET, is observed in most
EpS clinical samples [26]. We demonstrated that c-MET
was highly activated via an autocrine HGF loop in
both EpS cell lines. The HGF/c-MET signaling pathway
is critical in cell proliferation, motility, and invasion of
several human sarcomas [27-29], but little is known about
its biological functions in EpS.
In the present study, we first examined the therapeutic
efficacy of an mTOR inhibitor, RAD001 (everolimus;
Novartis Pharma AG, Basel, Switzerland), on two human
EpS cell lines, Asra-EPS and VAESBJ. Next, we investigated
whether RAD001-induced AKT reactivation was dependent
on c-MET signaling. Finally, to seek a novel therapeutic
modality for EpS, we evaluated the antitumor effects
of combining RAD001 with a c-MET inhibitor, INC280
(Novartis Pharma AG), on the growth of EpS cell lines
in vitro and in vivo.
Results
The AKT/mTOR pathway is constitutively hyperactivated
in EpS
To investigate whether the AKT/mTOR pathway was
activated in EpS, we examined the expression of its related
molecules in Asra-EPS and VAESBJ cells. AKT, mTOR,
and S6 ribosomal protein (S6RP) were more intensely
phosphorylated in Asra-EPS and VAESBJ cells than in
human dermal fibroblast (HDF) cells (KF4009; Kurabo,
Osaka, Japan), while INI-1 expression was completely lost
in both EpS cells (Figure 1A). These data indicated that
the AKT/mTOR pathway was hyperactivated in EpS.
Further, AKT phosphorylation was stronger in VAESBJ
cells than in Asra-EPS cells. PTEN, which negatively
regulated the AKT pathway [30], was less expressed
in VAESBJ cells (Figure 1A), suggesting the possibility
of marked AKT phosphorylation in these cells. We
observed that AKT phosphorylation was evident even in
the absence of serum in both EpS cell lines (Figure 1B),
indicating that EpS cells had an aberrant and constitutive
activation of AKT signaling.
RAD001 suppresses EpS cell growth but enhances
AKT activation
To assess the functional role of the AKT/mTOR pathway
in EpS, we first tested the effects of an mTOR inhibitor,
RAD001, on EpS cell proliferation in vitro. RAD001
treatment induced a dose-dependent decrease in the
proliferation of EpS cells compared with no significant
change in that of HDF cells (Figure 2A). To investigate
whether RAD001 inhibited EpS cell proliferation by
blocking mTOR signaling, we transfected two kinds of
anti-mTOR-specific siRNAs into each EpS cell line and
examined the effects of mTOR silencing. The expression
of mTOR and p-mTOR was inhibited by anti-mTOR
siRNAs in both EpS cells (Additional file 1: Figure S1A).
Figure 1 The AKT/mTOR pathway is constitutively activated in
Asra-EPS and VAESBJ cell lines. A) Expression of proteins related
to the AKT/mTOR pathway in Asra-EPS, VAESBJ, and HDF cells.
B) Expression of p-AKT in the absence or presence of serum in
Asra-EPS and VAESBJ cells. Cells were seeded in normal growth
medium, grown over night, and incubated in the absence or
presence of serum for 12 hours.
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suppressed VAESBJ cell proliferation and decreased
the anti-proliferative effect of RAD001 on VAESBJ cells
(Additional file 1: Figure S1B, C). These data suggested
that the AKT/mTOR signaling pathway affected EpS cell
growth and that RAD001 inhibited EpS cell proliferation
by blocking this pathway. RAD001 exposure increasedG0/G1 phase population and decreased S phase popula-
tion in a dose-dependent manner in both EpS cell lines
(Figure 2B), implying that the antitumor mechanism of
RAD001 primarily appeared to be exerted by G0/G1 cell
cycle arrest. Western blot analyses showed that S6RP
phosphorylation was inhibited after RAD001 treatment
in EpS but that AKT phosphorylation was increased
(Figure 2C). These results demonstrated that RAD001
blocked the mTOR pathway but enhanced AKT activation
in human EpS.
Subsequently, we evaluated the antitumor effects of
RAD001 on Asra-EPS xenograft tumor growth in nude
mice. The growth rate of Asra-EPS xenograft tumors
was delayed in RAD001-treated mice compared with that
in control-treated mice, although RAD001 treatment
did not induce tumor shrinkage (Figure 3A, B). Western
blot analyses exhibited a decrease in expression of
phosphorylated S6RP in RAD001-treated xenograft
tumors (Figure 3C), indicating that the mTOR signaling
was indeed blocked in vivo. Next, formalin-fixed and
paraffin-embedded tumor sections from mice of both
study arms were immunohistochemically evaluated. A
decrease in the rate of Ki-67-positive tumor cells and an
increase in expression of phosphorylated AKT were
observed in RAD001-treated tumors (Figure 3D–F). These
data showing tumor growth delay without shrinkage
suggested that RAD001-induced AKT reactivation may
decrease the activity of RAD001 and that agents blocking
this reactivation could enhance the antitumor effects of
RAD001 on the growth of EpS.
c-MET is highly activated through an autocrine
mechanism in EpS cells, and c-MET activation contributes
to EpS cell growth
Reportedly, mTOR inhibitors promoted AKT activation
by relieving feedback inhibition of RTK signaling [19-22].
To identify potential RTKs crucial for induction of AKT
phosphorylation in response to RAD001, we conducted
phospho-RTK array analyses and sought driver tyrosine
kinase in Asra-EPS and VAESBJ cells. c-MET was mark-
edly phosphorylated in both EpS cell lines (Figure 4A).
While c-MET was expressed but not phosphorylated in
SYO-1, a human synovial sarcoma cell line, or HDF cells,
higher expression and phosphorylation of c-MET were
observed in Asra-EPS and VAESBJ cells (Figure 4B). To
determine whether c-MET phosphorylation was caused
by an HGF autocrine loop in EpS, we examined the
expression of cell-secreted HGF by ELISA. As expected,
Asra-EPS and VAESBJ cells secreted high levels of HGF
into culture media, while SYO-1 or HDF cells did not
(Figure 4C). In addition, we also detected high amounts of
human HGF in the sera of mice bearing EpS xenograft
tumors (Figure 4C). The simultaneous expression of
c-MET and HGF and the basal level of p-MET in EpS
Figure 2 RAD001 inhibits EpS cell growth but increases AKT activation in vitro. A) Sensitivities of Asra-EPS, VAESBJ, and HDF cells to
RAD001. Cells were exposed to various concentrations of RAD001 for 72 hours. Cell viability was determined by WST-1 assay. Points, mean; bars,
SD. B) PI staining fluorescence-activated cell sorting analyses of the DNA contents of Asra-EPS and VAESBJ cells in response to RAD001. Cells were
treated with 0.25–4 nM of RAD001 or vehicle for 24 hours. C) Effects of RAD001 on phosphorylation of S6RP and AKT in Asra-EPS and VAESBJ cells.
Cells were treated with 0.25–4 nM of RAD001 or vehicle for 6 hours and with 1 nM RAD001 for 1–24 hours.
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constitutively stimulated through an autocrine mechanism.
To assess the role of the HGF/c-MET pathway in EpS cell
growth, we used RNA interference technology in vitro. Two
kinds of anti-c-MET-specific siRNAs were transfected into
EpS cells, which resulted in significant inhibition of c-MET
and p-MET expression (Figure 4D). The silencing of c-MET
expression decreased the proliferation and colony formationof EpS cells (Figure 4E, F). These findings suggested that the
HGF/c-MET signaling pathway affected EpS cell growth.
INC280 inhibits EpS cell growth, but the dependency of
VAESBJ cells on c-MET signaling differs from that of
Asra-EPS cells
A recently developed c-MET inhibitor, INC280, has
been shown to inhibit c-MET-dependent cell motility,
Figure 3 RAD001 delays Asra-EpS xenograft tumor growth but enhances AKT activation in vivo. A) Effects of RAD001 on Asra-EPS
xenograft tumor growth. Nude mice bearing Asra-EPS xenograft tumors were treated with 5 mg/kg RAD001 (n = 5) or vehicle control (n = 5)
thrice a week. Points, mean; bars, SD. *, p < 0.05, compared with control treatment. B) Asra-EPS xenograft tumor weights in control-treated and
RAD001-treated mice. The average tumor weight recorded at termination of the study was 1613 ± 1200 mg in the control group and 466 ± 269 mg in
the RAD001 group. Columns, mean; bars, SD. *, p < 0.05, compared with control treatment. C) Effects of RAD001 on S6RP phosphorylation in Asra-EPS
xenograft tumors. Tumors were harvested 3 hours after the last administration and then cell lysates were prepared. D) Immunohistochemical staining
of Ki-67 and p-AKT in control-treated and RAD001-treated Asra-EPS xenograft tumors. Scale bars: 100 μm. E) Ki-67-positivity rate of control-treated and
RAD001-treated Asra-EPS xenograft tumors. Columns, mean; bars, SD. *, p < 0.05, compared with control treatment. F) Relative expression levels of
p-AKT in control-treated and RAD001-treated Asra-EPS xenograft tumors. Relative expression levels were normalized against control-treated tumors.
Columns, mean; bars, SD. *, p < 0.05, compared with control treatment.
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in vitro and in vivo [31]. First, we tested the antitumor
effects of INC280 on the growth of Asra-EPS and VAESBJ
cells in vitro. Proliferation of Asra-EPS and VAESBJ cellswas suppressed in a dose-dependent manner by INC280
treatment, albeit with continuous proliferation of SYO-1
or HDF cells (Figure 5A). However, its anti-proliferative
effects were much higher on Asra-EPS cells than on
Figure 4 c-MET is highly activated through an autocrine mechanism in EpS, and c-MET activation affects EpS cell growth. A) Expression
of phosphorylated RTKs in Asra-EPS and VAESBJ cells. B) Protein expression of c-MET and p-MET in Asra-EPS, VAESBJ, SYO-1, and HDF cells.
C) HGF levels in cell-conditioned media and HGF serum concentrations in mice bearing xenograft tumors. Columns, mean; bars, SD. D) Expression
of c-MET and p-MET in Asra-EPS and VAESBJ cells transfected with anti-c-MET siRNAs or a control siRNA. E) Proliferation of Asra-EPS and VAESBJ
cells transfected with anti-c-MET siRNAs or a control siRNA. Cells transfected with siRNAs were cultured for 96 hours. Cell viability was determined
by WST-1 assay every 24 hours. Points, mean; bars, SD. **, p < 0.01, compared with control. F) Colony formation of Asra-EPS and VAESBJ cells
transfected with anti-c-MET siRNAs or a control siRNA. Columns, mean; bars, SD. **, p < 0.01, compared with control.
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showed that INC280 induced a greater increase in G0/G1
phase population in Asra-EPS cells than in VAESBJ cells
(Figure 5B). Cleavage of caspase-3 was induced after
INC280 exposure in a dose-dependent manner in
Asra-EPS cells, but its induction was hardly observed
in VAESBJ cells (Figure 5C). These data indicated thatAsra-EPS cells were more sensitive to INC280 than
VAESBJ cells because its effects inducing G0/G1 cell
cycle arrest and apoptosis were higher on Asra-EPS
cells than on VAESBJ cells.
Second, we examined the efficacy of INC280 on the
c-MET downstream pathways in Asra-EPS and VAESBJ
cells. The PI3K/AKT/mTOR and mitogen-activated protein
Figure 5 INC280 inhibits EpS cell growth in vitro, but Asra-EPS and VAESBJ cells differ from each other with regard to dependency on
c-MET signaling. A) Sensitivities of Asra-EPS, VAESBJ, SYO-1, and HDF cells to INC280. Cells were exposed to different concentrations of INC280
for 72 hours. Cell viability was determined by WST-1 assay. Points, mean; bars, SD. B) PI staining fluorescence-activated cell sorting analyses of the
DNA contents of Asra-EPS and VAESBJ cells in response to INC280. Asra-EPS and VAESBJ cells were incubated with 0.25–4 nM and 0.25–16 nM of
INC280 for 24 hours, respectively. C) Effects of INC280 on caspase-3 cleavage in Asra-EPS and VAESBJ cells. Cells were treated with 0.25–64 nM of
INC280 or vehicle for 24 hours. Staurosporine was used as a positive control. D) Effects of INC280 on phosphorylation of c-MET and its downstream
effectors in Asra-EPS and VAESBJ cells. Cells were treated with 0.25–4 nM of INC280 or vehicle for 1 hour.
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of c-MET signaling [25]. INC280 strikingly inhibited
phosphorylation of c-MET and its downstream moleculessuch as AKT and ERK in Asra-EPS cells but did not
decrease phosphorylation of AKT or ERK in HDF cells
(Figure 5D, Additional file 2: Figure S2). These results
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c-MET signaling. By contrast, INC280 remarkably blocked
phosphorylation of c-MET and ERK in VAESBJ cells,
but AKT phosphorylation was incompletely suppressed
(Figure 5D). These data indicated that compared with
Asra-EPS cells, VAESBJ cells were less dependent on
c-MET signaling in vitro, which resulted in sustained AKT
activation after INC280 treatment in VAESBJ cells.
We then evaluated the antitumor effects of INC280
on progression of VAESBJ xenograft tumors in mice. An
INC280 dose of 10 mg/kg given orally once a day was
selected on the basis of the previous observation that
this therapeutic dose resulted in inhibition of c-MET
phosphorylation in vivo [31]. The administration of
INC280 delayed VAESBJ xenograft tumor growth com-
pared with that of the vehicle control, whereas INC280-
treated tumors grew gradually (Figure 6A, B). Western
blot analyses demonstrated a decrease in expressionFigure 6 INC280 delays VAESBJ xenograft tumor growth in vivo. A) Ef
VAESBJ xenograft tumors were treated with 10 mg/kg INC280 (n = 5) or ve
compared with control treatment. B) VAESBJ xenograft tumor weight in cont
at termination of the study was 2112 ± 335 mg in the control group and 123
compared with control treatment. C) Effects of INC280 on c-MET phosphoryla
the last administration and then cell lysates were prepared. D) Immunohistoc
xenograft tumors. Scale bars: 100 μm. E) Ki-67-positivity rate of control-treated
SD. *, p < 0.05, compared with control treatment.of phosphorylated c-MET in INC280-treated tumors
(Figure 6C). Immunohistochemical studies showed a
decrease in the rate of Ki-67-positive tumor cells in
INC280-treated tumors compared with that in the
control-treated tumors (Figure 6D, E). These results
suggested that INC280 treatment exerted limited antitu-
mor effects on VAESBJ xenograft tumor growth by
blocking only c-MET signaling.
Activation of AKT and ERK is enhanced by RAD001
through a c-MET-dependent mechanism in EpS
Recently, mTOR inhibitors have been shown to increase
RTK activity and promote activation of not only AKT
but also ERK, which caused intrinsic resistance to
mTOR inhibitors [32]. Then, we evaluated the effects of
RAD001 on c-MET and its downstream AKT and ERK
in EpS. Phosphorylation of c-MET, AKT, and ERK was
increased after RAD001 treatment in Asra-EPS andfects of INC280 on VAESBJ xenograft tumor growth. Mice bearing
hicle control (n = 5) once a day. Points, mean; bars, SD. *, p < 0.05,
rol-treated and INC280-treated mice. The average tumor weight recorded
6 ± 145 mg in the INC280 group. Columns, mean; bars, SD. *, p < 0.05,
tion in VAESBJ xenograft tumors. Tumors were harvested 3 hours after
hemical staining of Ki-67 in control-treated and INC280-treated VAESBJ
and INC280-treated VAESBJ xenograft tumors. Columns, mean; bars,
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phosphorylation of AKT and ERK was attenuated by
silencing of c-MET in both EpS cell lines (Figure 7B).
These data implied that activation of AKT and ERK was
enhanced by mTOR inhibition with RAD001 through a
c-MET-dependent mechanism in EpS.
Combining RAD001 with INC280 remarkably inhibits EpS
cell growth in vitro
Because RAD001-induced reactivation of AKT and ERK
may limit the antitumor effects of RAD001, we investigated
the combined efficacy of RAD001 and INC280 on
EpS cell growth in vitro. Simultaneous administration
of both compounds remarkably inhibited the proliferation
of Asra-EPS and VAESBJ cells compared with either single
agent alone or a control (Figure 8A). Cell cycle analyses
revealed the superior effects of inducing G0/G1 cell-cycle
arrest by combined treatment with RAD001 and INC280
in both EpS cell lines (Figure 8B). The combination
of RAD001 and INC280 blocked RAD001-induced
phosphorylation of c-MET, AKT, and ERK in EpS
(Figure 8C). In addition, compared with INC280 alone,
the combination notably inhibited S6RP phosphorylation
(Figure 8C). These data indicated that the combination ofFigure 7 RAD001-induced activation of AKT and ERK is dependent on
phosphorylation of c-MET and its downstream effectors in Asra-EPS and VA
B) Effects of RAD001 on phosphorylation of AKT and ERK in Asra-EPS and V
transfected with siRNAs were treated with 1 nM RAD001 for 1 hour.RAD001 and INC280 exerted superior antitumor effects
on EpS cell growth by blocking both mTOR and c-MET
signaling pathways in vitro.
Combined therapy with RAD001 and INC280 significantly
abrogates EpS tumor growth in vivo
To assess the antitumor effects of combination therapy
with RAD001 and INC280 on EpS xenograft tumor
growth, a 4-armed therapeutic study was conducted.
Either RAD001 or INC280 as a single agent inhibited
Asra-EPS and VAESBJ xenograft tumor growth compared
with the vehicle control (Figure 9A–C). Most importantly,
combined treatment significantly abrogated EpS xenograft
tumor growth compared with the treatment with each
single drug alone (Figure 9A–C). No significant body
weight loss was observed in drug-treated mice bearing
Asra-EPS xenograft tumors (Figure 9D). Western blot
analyses showed that phosphorylation of both c-MET
and S6RP was blocked in combination-treated tumors
(Figure 9E). Immunohistochemical studies showed that
phosphorylation of AKTand ERK in Asra-EPS and VAESBJ
xenograft tumors was increased by RAD001 treatment but
attenuated by the combination therapy with RAD001
and INC280 (Figure 10A, Additional file 3: Figure S3).c-MET signaling pathway in EpS. A) Effects of RAD001 on
ESBJ cells. Cells were treated with 1 nM RAD001 for 5–360 minutes.
AESBJ cells transfected with anti-c-MET siRNAs or a control siRNA. Cells
Figure 8 Combination of RAD001 and INC280 surprisingly inhibits EpS cell growth by blocking the mTOR and c-MET pathways in vitro.
A) Combined efficacy of RAD001 and INC280 on EpS cell proliferation. Cells were treated with 10 nM INC280, 10 nM RAD001, their combination,
or vehicle for 72 hours. The cell number was counted every 24 hours. Points, mean; bars, SD. *, p < 0.05, **, p < 0.01, compared with control; #, p < 0.05,
compared with INC280 or RAD001 monotherapy. B) PI staining fluorescence-activated cell sorting analyses of the DNA contents of Asra-EPS and
VAESBJ cells in response to the combination of RAD001 and INC280. Cells were treated with 10 nM INC280, 10 nM RAD001, their combination, or
vehicle for 24 hours. C) Effects of combined treatment with RAD001 and INC280 on phosphorylation of c-MET and its downstream effectors. Cells were
treated with 10 nM INC280, 10 nM RAD001, their combination, or vehicle for 1 hour.
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ing cells was most pronounced in the combination-treated
tumors (Figure 10A, B). These data suggested that com-
bined inhibition of mTOR and c-MET signaling pathways
also exhibited significant antitumor effects on EpS in vivo.AKT and HGF/c-MET signaling pathways are frequently
activated in tumors of patients with EpS
To investigate the clinical relevance of AKT and
HGF/c-MET pathways in EpS, we examined expression of
p-AKT, HGF, c-MET, and p-MET in 6 EpS clinical
Figure 9 (See legend on next page.)
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Figure 9 Combined targeting of mTOR and c-MET results in superior antitumor effects on EpS tumor growth in vivo. A) Effects of
combination therapy with RAD001 and INC280 on EpS xenograft tumor growth. Mice bearing Asra-EPS and VAESBJ xenograft tumors were
treated with INC280 (n = 7), RAD001 (n = 7), their combination (n = 7), or vehicle control (n = 8). In the INC280 and combination groups, mice
were treated with 10 mg/kg INC280 once a day. In the RAD001 and combination groups, mice were treated with 5 mg/kg RAD001 thrice a week.
Points, mean; bars, SD. *, p < 0.05, **, p < 0.01, compared with control treatment; #, p < 0.05, compared with INC280 or RAD001 monotherapy.
B) Asra-EPS and VAESBJ xenograft tumor weight in the four groups. The average Asra-EPS tumor weights recorded at termination of the study
were: control group, 1106 ± 600 mg; INC280 group, 188 ± 113 mg; RAD001 group, 210 ± 93 mg; and combination group, 57 ± 40 mg. The average
VAESBJ tumor weights were: control group, 1337 ± 376 mg; INC280 group, 818 ± 311 mg; RAD001 group, 718 ± 195 mg; and combination group,
302 ± 77 mg. Columns, mean; bars, SD. *, p < 0.05, **, p < 0.01, compared with control treatment; #, p < 0.05, compared with INC280 or RAD001
monotherapy. C) Appearance of the resected Asra-EPS and VAESBJ xenograft tumors in the four groups. D) Body weight of mice bearing Asra-EPS
xenograft tumors in the four groups. Points, mean; bars, SD. E) Effects of combined therapy with RAD001 and INC280 on phosphorylation of S6RP and
c-MET in Asra-EPS and VAESBJ xenograft tumors. Xenograft tumors were harvested 3 hours after the last administration and then cell lysates
were prepared.
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different expression levels among the clinical samples of
EpS patients, p-AKT, HGF, and c-MET were expressed in
all 6 EpS samples, and p-MET expression was detected in
5 (83.3%) of 6 samples (Additional file 4: Figure S4,
Additional file 5: Table S1). These results indicated
that the activation of AKT and HGF/c-MET pathways
was frequently observed in tumors of patients with
EpS, as in EpS cell lines.
Discussion
Activation of the AKT/mTOR signaling pathway through
mutation of pathway components as well as through
activation of upstream signaling molecules occurs in a
majority of cancers and contributes to deregulation of
proliferation and resistance to apoptosis [6,7]. Constitutive
AKT activation was observed in MRTs characterized by
loss of INI-1 expression, and a mechanism for AKTactiva-
tion may be caused by aberrant activation of the insulin-
like growth factor 1 receptor (IGF-1R) pathway [33].
Moreover, AKT signaling was activated via autocrine
signaling by insulin and the insulin receptor in INI-1-
deficient AT/RTs [34]. In addition, INI-1 loss is observed
in the majority of EpS [11,12] and is responsible for the
tumorigenic properties of EpS [35], but it is unknown
whether the AKT/mTOR pathway is activated in EpS. In
the present study, we demonstrated loss of INI-1 expres-
sion and constitutive activation of the AKT/mTOR path-
way in two human EpS cell lines, Asra-EPS and VAESBJ.
Although the histological phenotypes of MRT, AT/RT,
and EpS are different from each other, INI-1 expression is
lost, and AKT signaling is activated among these distinct
tumors. However, little is known about the relationship
between INI-1 deficiency and AKT activation in EpS.
Asra-EPS and VAESBJ cell lines can be useful tools to
investigate this relationship in EpS.
mTOR inhibitors exert antitumor effects on several
cancers in which the AKT/mTOR pathway is hyperacti-
vated, but their effects are frequently modest in clinical trials
[17,18]. Biopsy samples from patients treated with mTORinhibitors confirmed that AKT reactivation occurred
clinically and portended a poorer prognosis [19,36].
AKT reactivation induced by mTOR inhibition in
tumor cells is likely to reduce its antitumor effects by
activating pathways that attenuate its effects on prolifera-
tion and apoptosis; thus, it is an unexpected and potentially
undesirable consequence of mTOR inhibition [19].
Recently, it has been shown that mTOR inhibitors
increased upstream RTK activity, which resulted in
reactivation of not only AKT but also ERK [32]. Here,
we demonstrated that an mTOR inhibitor, RAD001, also
inhibited EpS cell proliferation but induced reactivation of
both AKT and ERK. These results suggested that blockade
of this reactivation could enhance the antitumor effects of
mTOR inhibitors on EpS.
It has been reported that mTOR inhibitors induced
feedback reactivation of AKT signaling through an
IGF-1R-dependent, a platelet-derived growth factor
receptor A (PDGFRA)-dependent, or a PDGFRB-dependent
mechanism [19-22]. However, phospho-RTK array analyses
did not show activation of IGF-1R, PDGFRA, or PDGFRB
in EpS. Instead, we found that c-MET was the most highly
activated RTK in both EpS cell lines and that reactivation of
AKT and ERK by mTOR inhibition was c-MET-dependent
in EpS. To the best of our knowledge, this is the first study
to show that an mTOR inhibitor induces reactivation of
AKT and ERK through a c-MET-dependent mechanism.
These results provide a rationale for combining mTOR
inhibitors with c-MET inhibitors to treat patients with EpS.
HGF stimulation induces c-MET phosphorylation,
which in turn activates multiple downstream pathways,
including PI3K/AKT and MAPK/ERK signaling [25,37].
Combined overexpression of HGF and c-MET have been
observed in numerous sarcomas [38-40], and HGF can
activate c-MET in an autocrine manner in these tumors.
We observed that both HGF and c-MET were also
overexpressed in Asra-EPS and VAESBJ cells, indicating
that c-MET was aberrantly activated by autocrine HGF
stimulation in EpS. Cancer-associated c-MET activation
triggers cell growth, survival, invasion, migration, and
Figure 10 Combination therapy decreases RAD001-induced activation of AKT and ERK in EpS xenograft tumors. A) Immunohistochemical
staining of p-AKT, p-ERK, and Ki-67 in Asra-EPS and VAESBJ xenograft tumors in the four groups. Scale bars: 100 μm. B) Ki-67-positivity rate of Asra-EPS
and VAESBJ xenograft tumors in the four groups. Columns, mean; bars, SD. *, p < 0.05, **, p < 0.01, compared with control treatment; #, p < 0.05,
compared with INC280 or RAD001 monotherapy.
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antitumor efficacy in preclinical studies and are currently
being evaluated in human cancer clinical trials [44,45]. In
the present study, a selective c-MET inhibitor INC280
showed antitumor effects on EpS cell growth by blocking
activation of AKT and ERK. These data indicated that one
mechanism for activation of both AKT and ERK pathways
was based on the HGF/c-MET autocrine signaling in EpS.
However, the sensitivity of VAESBJ cells to INC280
was modest compared with that of Asra-EPS cells.
AKT activation was completely blocked by treatment
with INC280 in Asra-EPS cells but not in VAESBJcells. These results suggested that the dependency of
VAESBJ cells on HGF/c-MET signaling may differ from
that of Asra-EPS cells.
PTEN counteracts the effects of PI3K on AKT, and
loss of PTEN expression mediates AKT activation
[30]. PTEN status affected anti-c-MET therapies to
glioblastomas in which PTEN protein expression was
frequently low or absent, and combining anti-HGF/c-MET
therapies with mTOR inhibitors additively inhibited growth
of glioblastoma xenografts [46]. Xie and colleagues
demonstrated no or reduced PTEN expression in many
EpS samples, indicating that PTEN deregulation was a
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found that PTEN expression was much lower in VAESBJ
cells than in Asra-EPS or control HDF cells, suggesting
that epithelioid sarcomas were heterogeneous malignan-
cies in terms of PTEN expression. Our results indicated
that reduction of PTEN expression in VAESBJ cells
may contribute to sustained AKT activation after
INC280 treatment and result in decreased sensitivity
to c-MET inhibitors.
In fact, the growth of EpS was also significantly
abrogated by treatment with the combination of RAD001
and INC280 in vitro and in vivo. Their combination
notably inhibited mTOR and c-MET signaling pathways
that were hyperactivated in human EpS; thus, we propose
a combined therapeutic approach using mTOR and
c-MET inhibitors for EpS lacking effective systemic
treatment.
In the present study, the expression of proteins related
to AKT/mTOR and HGF/c-MET pathways were detected
in nearly all EpS clinical samples, as in EpS cell lines.
However, expression levels of these proteins were different
among the clinical samples of EpS patients. These results
in clinical and experimental studies suggested that EpS
cells exhibited heterogeneity in dependency on AKT and
c-MET pathways within the tumor. The activation of
these pathways contributes to the cell proliferation,
survival, and resistance to chemotherapies in many
cancers [6,7,37,41-43]. Therefore, dual targeting of
AKT/mTOR and HGF/c-MET pathways may exert
significant antitumor effects on EpS cells in which
these pathways are activated and help us to overcome
this devastating disease.
Conclusions
Loss of INI-1 expression and constitutive AKT activation
were observed in Asra-EPS and VAESBJ cells. EpS cell
proliferation was inhibited by treatment with RAD001
in vitro and in vivo, but reactivation of AKT and ERK
through a c-MET-dependent mechanism occurred after
RAD001 treatment in EpS. RAD001 combined with
INC280 exhibited significant antitumor effects on EpS
cell lines both in vitro and in vivo. Hence our preclinical
data suggest that combined targeting of mTOR and
c-MET signaling pathways should be a novel and effective
strategy for treatment of human EpS.
Materials and methods
Cell lines, reagents, and antibodies
We used two human EpS cell lines, Asra-EPS and
VAESBJ. Asra-EPS was established from a primary tumor of
the patient with angiomatoid type of EpS in our laboratory
as previously described [13]. VAESBJ, which was established
from a bone marrow aspirate of the patient with EpS whose
tumors metastasized to a bone marrow [14], was purchasedfrom the American Type Culture Collection. HDF cells
were purchased from Kurabo. A human synovial sarcoma
cell line, SYO-1, was kindly provided by Dr. Ozaki
(Okayama University, Okayama, Japan). Cells were grown
in Dulbecco’s Modified Eagle Medium (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% FBS
(Sigma-Aldrich, St. Louis, MO, USA). Cells were cultured
in a humidified atmosphere at 37°C in 5% CO2.
An mTOR inhibitor, RAD001, and an ATP-competitive
selective c-MET inhibitor, INC280, were provided by
Novartis Pharma AG. According to the manufacturer’s
instructions, RAD001 and INC280 were prepared in
dimethyl sulfoxide (DMSO) before being added to cell
cultures for in vitro studies. The oral RAD001 formulation
provided by Novartis Pharma AG (everolimus microemul-
sion preconcentrate and corresponding placebo) for
animal experiments was diluted with water to the optimal
concentration just before administration via gavage.
INC280 was diluted in 0.5% methylcellulose and 0.1%
Tween 80 for in vivo experiments.
Antibodies against c-MET (#8198; WB, 1:1000; IHC,
1:300), p-MET (Tyr1234/1235; #3077; WB, 1:1000; IHC,
1:150), AKT (#4691; 1:1000), p-AKT (Ser473; #4060; WB,
1:1000; IHC, 1:50), ERK (#4695; 1:1000), p-ERK (Thr202/
Tyr204; #4370; WB, 1:2000; IHC, 1:400), mTOR (#2983;
1:1000), p-mTOR (Ser2448; #5536; 1:1000), S6RP (#2217;
1:1000), p-S6RP (Ser235/236; #2211; 1:1000), PTEN
(#9188; 1:1000), cleaved caspase-3 (#9661; 1:1000), and
beta-actin (#4970; 1:1000) were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). An
antibody against Ki-67 (M7240; 1:50) was purchased
from Dako (Glostrup, Denmark). An antibody against
INI-1 (612110; 1:500) was purchased from Becton
Dickinson Biosciences (BD Biosciences; San Jose, CA,
USA). An antibody against HGF (AF-294-NA; 10 μg/ml)
was purchased from R&D systems (Minneapolis, MN,
USA). Horseradish peroxidase (HRP)-conjugated secondary
antibodies were purchased from GE Healthcare Life
Sciences (Piscataway, NJ, USA).
Patients
Six patients with EpS (5 males and 1 female) were operated
in Osaka University Hospital from 1998 to 2012. The
mean age at the operation was 59.5 years (49 to 67). Tumor
specimens were obtained with the patients’ informed
consent and used for immunohistochemical studies.
Western blot analysis
For the lysate preparation, cells were first washed
with PBS and lysed in RIPA buffer (Thermo Scientific,
Waltham, MA, USA). Protein concentrations were
determined according to the bicinchoninic acid method
(Thermo Scientific). Then, the cell lysates were separated
on 4%–12% Bis-Tris gels (Life Technologies) and transferred
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Genetics, Tokyo, Japan). The membranes were incubated in
5% skim milk in TBS with Tween 20 (TBS-T) at room
temperature. Blocked membranes were incubated with
primary antibodies at 4°C overnight, followed by incuba-
tion with secondary antibodies at room temperature for
1 hour. After washing in TBS-T, immunoreactive bands
were visualized by enhanced chemiluminescence (ECL;
GE Healthcare Life Sciences).
WST-1 cell proliferation assay
Cells were seeded at a density of 1 × 103 cells/well in
96-well plates for cell proliferation assays. The cells
were incubated overnight and treated with various
concentrations of drugs or vehicle (DMSO) for drug
experiments. Cell viability was assessed using the Premix
WST-1 cell proliferation assay system (Takara Bio, Inc.,
Otsu, Japan). Using a microplate reader, absorbance
measurements read at 690 nm were subtracted from those
read at 450 nm. Relative cell viability was expressed as
(absorbance of treated cells minus absorbance of cell-free
control)/(absorbance of untreated control minus absorb-
ance of cell-free control).
Cell cycle analysis
EpS cells were seeded at a density of 5 × 105 cells/dish in
10-cm culture dishes and grown overnight, followed
by treatment with RAD001, INC280, their combination,
or vehicle. After 24-hour treatment, the cells were
collected and stained with propidium iodide (PI) solution
(25 μg/ml PI, 0.03% NP-40, 0.02 mg/ml RNase A, 0.1%
sodium citrate) for 30 minutes at room temperature.
The cell cycle was analyzed using BD FACSCanto II
flow cytometer (BD Biosciences).
In vivo animal xenograft models
Five-week-old athymic nude mice (BALB/c nu/nu;
SLC, Shizuoka, Japan) were housed at the Institute of
Experimental Animal Sciences Osaka University Medical
School, in accordance with a guideline approved by the In-
stitutional Animal Care and Use Committee of the Osaka
University Graduate School of Medicine. For the xenograft
tumor growth assay, 1 × 107 EpS cells were injected sub-
cutaneously into the left side of the back. Therapy was
initiated after tumor establishment (>5 mm in the longest
diameter). RAD001 and INC280 were administered
orally thrice a week and once a day, respectively. Xeno-
graft tumor volume and mice body weight were mea-
sured twice a week. Tumor volume was measured with
a caliper and calculated according to the formula (A ×
B2)/2, with A being the longest diameter and B the
shortest diameter of the tumor. Mice were sacrificed
when the total tumor burden reached 2 cm3, and the
tumor weight was then measured. The tumors wereresected for western blot analyses and immunohisto-
chemical studies.
Immunohistochemistry
Specimens of tumors formed in nude mice and those
of patients’ primary tumors were fixed in 10%
neutral-buffered formalin, embedded in paraffin, and
sectioned in 4-μm thicknesses. Paraffin-embedded sections
were deparaffinized and dehydrated. Antigens were
retrieved at 95°C for 10 minutes in a 10-mM citrate
buffer. After blocking of endogenous peroxidase activity
for 10 minutes with methanol containing 3% H2O2, the
sections were reacted for 1 hour with TBS containing
2% bovine serum albumin at room temperature. The
sections were incubated with primary antibodies at 4°C
overnight. On the next day, sections were incubated
for 1 hour with secondary antibodies and stained with
3,3’-diaminobenzidine tetrahydrochloride (DAB; Dako).
The sections were finally counterstained with hematoxylin.
Immunohistochemical protein expression levels were deter-
mined using NIS-Elements software (Nikon Corporation,
Tokyo, Japan). Staining of p-AKT, HGF, c-MET, and
p-MET in patients’ clinical samples was scored as follows:
0, undetectable (0% positive cells); 1+, focally positive
(<10% positive cells); 2+, moderately positive (<50%
positive cells), and 3+, intensely positive (more than
50% positive cells). Immunohistochemical results were
interpreted as negative (0, 1+) or positive (2+, 3+).
Phospho-RTK array
To evaluate expression of phosphorylated RTKs, the
phospho-RTK array was performed with the Proteome
Profiler Array Kit (R&D Systems), according to the manu-
facturer’s protocol. In brief, the array membrane was
blocked for 1 hour, incubated with cell lysates overnight,
and then treated with HRP-conjugated anti-phospho-
tyrosine antibody for 2 hours at room temperature. The
membrane was developed with ECL detection reagent,
and RTK spots were visualized.
ELISA
Cells were cultured at a density of 1 × 105 cells/well
in 6-well plates. On the 4th day, cell culture supernatants
were collected. When xenograft tumors reached 2 cm3,
whole blood samples were collected by intracardiac
puncture, and sera were obtained. HGF concentrations in
cell-conditioned media or sera of xenografted mice were
determined by ELISA using a Human HGF Quantikine
ELISA kit (R&D Systems), according to the manufacturer’s
instruction.
siRNA transfection
EpS cells were seeded at a density of 3 × 105 cells/well in
6-well plates and grown overnight. Cells were transfected
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2000 (Life Technologies). Two kinds of siRNAs targeting
c-MET (constructs I and II; #6618 and #6622) and mTOR
(construct I and II; #6381 and #6556), and a non-targeting
siRNA (#6568) were purchased from Cell Signaling
Technology, Inc.
Soft agar colony formation assay
Five thousand EpS cells were suspended in 1 ml of 0.5%
SeaPlaque Agarose (Lonza, Basel, Switzerland) with
normal growth medium and seeded over a basal layer
of 0.6% agarose in 35-mm culture dishes. The number
of colonies (>100 μm in diameter) per well was counted
under a light microscope two weeks later.
Determination of cell number
EpS cells were plated at a density of 1 × 105 cells/well
into 6-well plates and grown overnight before treatment
with RAD001, INC280, their combination, or vehicle for
72 hours. Cells were trypsinized with 0.25% trypsin plus
EDTA (Life Technologies), and a hemocytometer was used
to count the cell number for each well every 24 hours.
Statistical analysis
Each experiment was performed in triplicate. All data are
expressed as means ± SDs. Student’s t-test for biological
assays and Mann–Whitney’s U test for animal experiments
were used to evaluate the significance of differences. Values
of p < 0.05 were considered statistically significant.
Additional files
Additional file 1: Figure S1. A) Expression of mTOR and p-mTOR in
VAESBJ and Asra-EPS cells transfected with anti-mTOR siRNAs or a control
siRNA. B) Relative cell viability of VAESBJ cells transfected with anti-mTOR
siRNAs or a control siRNA. Cells transfected with siRNAs were cultured for
72 hours. Cell viability was determined by WST-1 assay. Relative cell viability
was normalized against cells transfected with a non-targeting siRNA.
Columns, mean; bars, SD. *, p < 0.05, **, p < 0.01, compared with control.
C) Sensitivities of VAESBJ cells transfected with anti-mTOR siRNAs or a
control siRNA to various concentrations of RAD001. Cell viability was
measured 72-hour after RAD001 treatment using the WST-1 assay. Relative
cell viability was normalized against drug-untreated cells transfected with a
non-targeting siRNA. Points, mean; bars, SD.
Additional file 2: Figure S2. Effects of INC280 on phosphorylation of
AKT and ERK in HDF cells. The cells were treated with 10 nM INC280 or
vehicle for 1 hour.
Additional file 3: Figure S3. A) Relative expression levels of p-AKT in
Asra-EPS and VAESBJ xenograft tumors in the four groups using NIS-Elements
software (Nikon Corporation). Relative expression levels were normalized
against control-treated tumors. Columns, mean; bars, SD. *, p < 0.05. B)
Relative expression levels of p-ERK in Asra-EPS and VAESBJ xenograft tumors
in the four groups. Relative expression levels were normalized against
control-treated tumors. Columns, mean; bars, SD. *, p < 0.05.
Additional file 4: Figure S4. Immunohistochemical expression of
p-AKT, HGF, c-MET, and p-MET in 6 EpS clinical samples. Scale bars: 100 μm.
Additional file 5: Table S1. Scoring of p-AKT, HGF, c-MET, and p-MET
staining in patients’ clinical samples. Scores of 0 or 1+ were defined as
negative and those of 2+ or 3+ as positive.Abbreviations
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